Yang Z - Search Results

1

Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers.

Zou L, Qi Y, Jiang Y, Tang L, Du Y, Zhao B, Sun Y, Xiang M, Ma J, Yang Z. Zou L, et al. Among authors: yang z. Cancer Commun (Lond). 2023 Feb;43(2):171-176. doi: 10.1002/cac2.12400. Epub 2023 Jan 22. Cancer Commun (Lond). 2023. PMID: 36683350 Free PMC article. No abstract available.

2

China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.

Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, Hao R, Pan J, Zhao X, Chen D, Song Y, Qi Y, Tang L, Liu Z, Gao R, Shi Y, Yang Z. Zhou M, et al. Among authors: yang z. Cancer Commun (Lond). 2019 Jun 20;39(1):36. doi: 10.1186/s40880-019-0383-7. Cancer Commun (Lond). 2019. PMID: 31221221 Free PMC article. Review.

3

[Consideration on the Research and Development of New Drugs for Rare Tumors].

Tang L, Song Y, Yang Z. Tang L, et al. Among authors: yang z. Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):443-447. doi: 10.3779/j.issn.1009-3419.2022.101.26. Zhongguo Fei Ai Za Zhi. 2022. PMID: 35899439 Free PMC article. Chinese.

4

[Considerations on Clinical Development and Regulatory of the Oversea License-in  Anti-tumor Drugs].

Zhao X, Hao R, Tong X, Zou L, Tang L, Zhang H, Xia L, Yang Z. Zhao X, et al. Among authors: yang z. Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):448-451. doi: 10.3779/j.issn.1009-3419.2022.101.27. Zhongguo Fei Ai Za Zhi. 2022. PMID: 35899440 Free PMC article. Chinese.

5

[Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs].

Song Y, Tang L, Xia L, Tong X, Yang Z. Song Y, et al. Among authors: yang z. Zhongguo Fei Ai Za Zhi. 2022 Sep 20;25(9):684-688. doi: 10.3779/j.issn.1009-3419.2022.101.43. Zhongguo Fei Ai Za Zhi. 2022. PMID: 36172734 Free PMC article. Chinese.

6

Clinical review considerations of class I PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation.

Zou L, Qi Y, Tang L, Du Y, Xiang M, Chen X, Ma J, Yang Z. Zou L, et al. Among authors: yang z. Chin J Cancer Res. 2022 Aug 30;34(4):415-421. doi: 10.21147/j.issn.1000-9604.2022.04.09. Chin J Cancer Res. 2022. PMID: 36199534 Free PMC article.

7

Regulatory considerations for paediatric drug evaluation in China.

Geng Y, Li Q, Sun YZ, Zhang H, Jiang YL, Wang LQ, Wu YE, Zhao W, Yang ZM. Geng Y, et al. BMJ Paediatr Open. 2023 May;7(1):e001666. doi: 10.1136/bmjpo-2022-001666. BMJ Paediatr Open. 2023. PMID: 37130653 Free PMC article. Review.

8

The changing landscape of clinical trial and approval processes in China.

Zhou Q, Chen XY, Yang ZM, Wu YL. Zhou Q, et al. Nat Rev Clin Oncol. 2017 Sep;14(9):577-583. doi: 10.1038/nrclinonc.2017.10. Epub 2017 Feb 14. Nat Rev Clin Oncol. 2017. PMID: 28195238 Review.

9

Clinical development of immuno-oncology in China.

Wu DW, Huang HY, Tang Y, Zhao Y, Yang ZM, Wang J, Wang SH, Yu Y, Fang Y, Fang H, Bai Y, Sun C, Fan Q, Yu AQ, Wang HL, Du CX, Chen K, Huang MD, Zhang Y, Li N, Xu BH, Sun Y, He J. Wu DW, et al. Lancet Oncol. 2020 Aug;21(8):1013-1016. doi: 10.1016/S1470-2045(20)30329-6. Lancet Oncol. 2020. PMID: 32758460 No abstract available.

10

Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs.

Zhao S, Wang D, Zhao H, Gong J, Zhang J, Fang W, Ma F, Xu B, Li J, Hu X, Ba Y, Chen X, Yang Z, Shen L, Jiang J, Zhang L; Chinese Phase 1 Oncology Trial Consortium. Zhao S, et al. Among authors: yang z. Cancer Cell. 2022 Mar 14;40(3):233-235. doi: 10.1016/j.ccell.2022.01.007. Epub 2022 Feb 24. Cancer Cell. 2022. PMID: 35290782 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45,904 results

Search Page